3种方案根除幽门螺杆菌的药物经济学分析

Cost-benefit analysis of three schedule for treating helicobacter pylori

目的观察3种方案根除幽门螺杆菌(helicobacter pylori,Hp)药物成本与效果的关系。方法 182例患者随机分为3组:A组64例,给予雷贝拉唑10mg,克拉霉素0.5g,呋喃唑酮0.1g,每天2次;B组61例,给予奥美拉唑20mg,呋喃唑酮0.1g,替硝唑0.4g,每天2次;C组57例,给予奥美拉唑20mg,克拉霉素0.5g,阿莫西林1.0g,每天2次;1周后停药并分析疗效及药物经济学。结果 3种方案药品成本分别为148.40、8.55、146.95元,有效率分别为92.2%、90.2%、86.0%,差异无统计学意义(P>0.05);B组成本-效果分析及敏感度均优于A组和C组,差异均有统计学意义(P<0.05)。结论 A治疗方案疗效可靠,价格合理,经济条件较好可以使用;B方案疗效可靠,价格便宜,农村患者可以推广;C方案疗效稍逊一筹,价格昂贵,不宜推广。

Objective To observe the relations between drug cost and effectiveness of3 kinds for helicobacteria pylori （Hp）. Methods 182 patietns were randomly assigned to receive colloidal rabeprazole 10mg ＋ clarithromycin 0. 5g ＋ furazoli-done 0. 1g（group A,64 cases）,2 times a day;Colloidal omeprazole 20mg ＋ furazolidone 0. 1g ＋ Tinidazole 0. 4g（group B,61 cases）,2 times a day;Colloidal omeprazole 20mg ＋ clarithromycin 0. 5g ＋ amoxicillin 1. 0g（group C,57 cases）,2 times a day. The course of treatment was l week for three groups,and analysed the efficacy and pharmacoeconomics. Results The cost of 3 kinds of pharmacotherapentic schemes were 148. 40,8. 55 and 146. 95 yuan,the eradication rates of helicobacter pylori were 92. 2% ,90. 2% and 86. 0% ,the difference was not statistically significant（P 0. 05）;Cost-effectiveness analysis and sensitivity of B group were better than that in A group and C group,the differences were statistically significant（P 0. 05）. Conclusion The pharmacotherapentic schemes of A was effective,not so expensive,can be used for the patients who were rich;The pharmaeotherapentic schemes of B was cheap while effective in helieobacter pylofi eradication,can be used clinically;The phar-macotherapentic schemes of C was so expensive while poor effective,can not be used clinically.